The chronic idiopathic constipation market size reached a value of USD 6.6 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 11.0 Billion by 2035, exhibiting a growth rate (CAGR) of 4.71% during 2025-2035.

The market for Chronic Idiopathic Constipation (CIC) is experiencing significant advances in 2025 due to heightened awareness, increased incidence, and a new wave of technological innovation. Defined by the passage of infrequent bowel movements and difficult defecation with no underlying pathology, CIC can significantly reduce one’s quality of life. Long-term relief is increasingly sought by patients, driving the market to respond with strategies that integrate lifestyle modifications, advanced diagnostics, and novel therapeutics.  

Increasing prevalence drives changes in healthcare delivery models  

The elderly population aged fifty years and above are the most affected, alongside individuals with sedentary lifestyles or poor dietary habits. Shifts toward remote healthcare models due to recent global disruptions have led to increased use of gut motility affecting medications, as well as more open conversations surrounding digestive health. Bowel examinations are now a routine part of telehealth consultations, and providers are screening for chronic constipation far earlier than the historical average. Patients’ awareness of CIC’s physical discomforts and emotional burdens has risen, leading to much greater demand, thus transforming the market for comprehensive and effective solutions.

Transformative Market Developments in 2025  

An important development within the CIC market is the shift from treating acute symptoms to managing and preventing chronic conditions. Although traditional laxatives continue to be used, patients and healthcare providers are increasingly leaning toward long-acting prescription treatments that promote regular bowel movements in a gut-friendly manner. These include prescription formulations like guanylate cyclase-C agonists and serotonin-4 receptor modulators that resolve motility problems instead of merely softening stools.  

In addition, there is a growing personalization of care pathways. Diagnosis now integrates symptom log, digital bowel diaries, and scoring systems to document and evaluate symptoms. Many patients start with coaching on lifestyles and diets—high fiber, sufficient fluids, and physical activity—before progressing to pharmacotherapy. This tiered approach to care not only enhances provider understanding of symptom and treatment dynamics but also enables patient empowerment in managing their health.  

Technological Innovations Facilitating Change  

The year 2025 will see the use of digital tools in diagnosing and managing CIC streamlining processes. With mobile applications, users can log their bowel movements, pain levels, and even diet. This is crucial in identifying patterns, which is invaluable for providing timely intervention. With these apps, patients also receive reminders on hydration, physical activity, and medication schedules, which help reinforce positive behaviors and enhance adherence to treatment.

The innovation of technology used for diagnostics is also progressing. Mobile phone connected gut motility monitors and non–invasive imaging techniques are now being used in practice. These devices monitor colonic transit, stool, and defecation patterns quantifying bowel movements over the clinic’s baseline. This approach provides valuable preliminary assessment without requiring invasive techniques and enables more precise baseline evaluation during the initial assessment. In addition, the data gathered is important for modifying treatment in real time based on patient response. In the device sector, biofeedback systems are improving in accuracy and ease of use. They are lending themselves to self-guided rehab through sensor-based pelvic floor muscle training resulting in improved autonomy and faster achievement of bowel retraining goals. Such devices are crucial in pelvic floor disorders which often coexist with chronic idiopathic constipation.  

Patient care and experience integration  

Another new development expected in 2025 is integrated care for chronic idiopathic constipation (CIC). The medical team now consists of gastroenterologists, dieticians, and physiotherapists who work collaboratively to manage the condition holistically. Telemedicine follow-up appointments, virtual group classes, and online support groups are facilitating adherence to lifestyle and therapy regimens. These multidisciplinary approaches are designed to manage symptom exacerbations and enhance long-term comfort.

Looking Ahead

The chronic idiopathic constipation market is expected to shift towards more patient-centered approaches by the year 2025. The growing prevalence of chronic idiopathic constipation (CIC) coupled with increased patient participation is creating demand for more sustainable treatment approaches that promote digestive health—free of quick-fix methods. Through advancements in prescription medications, digital trackers, non-invasive diagnostic tools, and biofeedback, the market is positioned to enhance health and quality of life. With telehealth remaining a staple, patients are able to receive tailored healthcare from the comfort of their homes, allowing them to manage their CIC more easily and confidently.

Request for a sample of this report: https://www.imarcgroup.com/chronic-idiopathic-constipation-market/requestsample

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic idiopathic constipation market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic idiopathic constipation market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current chronic idiopathic constipation marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the chronic idiopathic constipation market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Ironwood Pharmaceuticals

2. Takeda

3. Sebela Pharmaceuticals

4. Bausch Health Companies

5. Mallinckrodt

Explore Bacterial Vaginosis Market Epidemiology report 2025-2035: https://www.imarcgroup.com/request?type=report&id=7985&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145